| Literature DB >> 31723055 |
Oren Yifa1, Karen Weisinger1, Elad Bassat1, Hanjun Li2, David Kain1, Haim Barr3, Noga Kozer3, Alexander Genzelinakh1, Dana Rajchman1, Tamar Eigler1, Kfir Baruch Umansky1, Daria Lendengolts1, Ori Brener4, Nenad Bursac2, Eldad Tzahor1.
Abstract
The adult mammalian heart regenerates poorly after injury and, as a result, ischemic heart diseases are among the leading causes of death worldwide. The recovery of the injured heart is dependent on orchestrated repair processes including inflammation, fibrosis, cardiomyocyte survival, proliferation, and contraction properties that could be modulated in patients. In this work we designed an automated high-throughput screening system for small molecules that induce cardiomyocyte proliferation in vitro and identified the small molecule Chicago Sky Blue 6B (CSB). Following induced myocardial infarction, CSB treatment reduced scar size and improved heart function of adult mice. Mechanistically, we show that although initially identified using in vitro screening for cardiomyocyte proliferation, in the adult mouse CSB promotes heart repair through (i) inhibition of CaMKII signaling, which improves cardiomyocyte contractility; and (ii) inhibition of neutrophil and macrophage activation, which attenuates the acute inflammatory response, thereby contributing to reduced scarring. In summary, we identified CSB as a potential therapeutic agent that enhances cardiac repair and function by suppressing postinjury detrimental processes, with no evidence for cardiomyocyte renewal.Entities:
Keywords: Cardiology; Cardiovascular disease; Drug screens; Heart failure; Therapeutics
Year: 2019 PMID: 31723055 PMCID: PMC6948869 DOI: 10.1172/jci.insight.128025
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708